Home Current Issue Previous Issues Epub Ahead Reports CME Podcasts Grand Rounds For Authors Journal Info
Skip Navigation LinksHome > June 2004 - Volume 56 - Issue 6 > Preventing Renal Failure in Patients with Rhabdomyolysis: Do...
Journal of Trauma-Injury Infection & Critical Care:
Original Articles

Preventing Renal Failure in Patients with Rhabdomyolysis: Do Bicarbonate and Mannitol Make a Difference?

Brown, Carlos V. R. MD; Rhee, Peter MD, MPH; Chan, Linda PhD; Evans, Kelly MS; Demetriades, Demetrios MD, PhD; Velmahos, George C. MD, PhD

Collapse Box

Abstract

Background: The combination of bicarbonate and mannitol (BIC/MAN) is commonly used to prevent renal failure (RF) in patients with rhabdomyolysis despite the absence of sufficient evidence validating its use. The purpose of this study was to determine whether BIC/ MAN is effective in preventing RF in patients with rhabdomyolysis caused by trauma.

Methods: This study was a review of all adult trauma intensive care unit (ICU) admissions over 5 years (January 1997–September 2002). Creatine kinase (CK) levels were checked daily (abnormal,>520 U/L). RF was defined as a creatinine greater than 2.0 mg/dL. Patients received BIC/MAN on the basis of the surgeon’s discretion.

Results: Among 2,083 trauma ICU admissions, 85% had abnormal CK levels. Overall, RF occurred in 10% of trauma ICU patients. A CK level of 5,000 U/L was the lowest abnormal level associated with RF; 74 of 382 (19%) patients with CK greater than 5,000 U/L developed RF as compared with 143 of 1,701 (8%) patients with CK less than 5,000 U/L (p < 0.0001). Among patients with CK greater than 5,000 U/L, there was no difference in the rates of RF, dialysis, or mortality between those who received BIC/MAN and those who did not. Subanalysis of groups with various levels of CK still failed to show any benefit of BIC/MAN.

Conclusion: Abnormal CK levels are common among critically injured patients, and a CK level greater than 5,000 U/L is associated with RF. BIC/MAN does not prevent RF, dialysis, or mortality in patients with creatine kinase levels greater than 5,000 U/L. The standard of administering BIC/MAN to patients with post-traumatic rhabdomyolysis should be reevaluated.

© 2004 Lippincott Williams & Wilkins, Inc.

Follow Us


Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.